Clinical OMICS

JUL-AUG 2017

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/853204

Contents of this Issue

Navigation

Page 27 of 47

26 Clinical OMICs July/August 2017 www.clinicalomics.com I t has been roughly nine years since next-generation sequencing (NGS) meth- ods made their appearance in research labs. Largely led—at least initially—by sequencing heavyweight Illumina, the new technologies allowed researchers and molecular biologists in clinical labs to move from sequencing single genes to today where it is routinely used to analyze panels of hundreds of genes in a single run. The steady migration of NGS from the research lab to a diagnostic tool in the clinical lab is the result of the combined effects of dramatically decreasing costs, improvements in the accuracy and specificity of NGS platforms, and the applica- tion of data from sequencing experiments that have unlocked our understanding of the genetic underpinnings of disease. Yet, amid these positive developments, NGS first had to prove itself against existing and estab- lished technologies. "Initially, (using NGS) was all about 'can I match what I get with PCR,' or 'can I match what I get with FISH,' or something else," said Joydeep Goswami, Ph.D., president, clinical NGS and oncology with Thermo Fisher Scientific. "Today, we are seeing those concerns melt away. Clinicians are comfortable and pathol- ogists are comfortable enough with the NGS readout that they don't need to do confirmatory studies every time they get a result." According to Geoff Otto, Ph.D., vice president of clinical product development and strategy at Foundation Medicine, NGS first started making its bones as a diagnostics platform to detect germline mutations. This led to the development of noninvasive prenatal testing, tests for single genes known to be associated with disease such as cystic fibrosis, and also some limited cancer tests. "Around seven or eight years ago, NGS reached a point where it started to generate the kind of information required to inform what was going on in human genomics—at the necessary scale, throughput, and accuracy for these tests," Dr. Otto said. "That was the backdrop. But it was not entirely clear you could apply Deeper Diagnostic Dive Diagnostics Leveraging Next-Generation Sequencing Become Mainstream for Cancer and Rare Diseases Chris Anderson Editor in Chief "We are rapidly reaching the point where we will do whole–genome sequencing on anybody you think has a rare disease."—David Bick, M.D., HudsonAlpha Institute's Smith Family Clinic for Genomic Medicine.

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JUL-AUG 2017